Remove 2030 Remove Drug Development Remove Small Molecule
article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Food and Drug Administrations (FDA) diversity and inclusion in clinical trials mandate. However, it is representative of the average across most of todays trials, where only 2030% of participants are women. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.